
SILENCE DISEASE. AMPLIFY LIFE.™ Alnylam is a leading independent biopharmaceutical company and the pioneer in RNA interference (RNAi) therapeutics – a revolutionary approach to treating diseases which “silences” the genes that cause or contribute to them. Founded in 2002 by a group of distinguished researchers and biotech leaders, Alnylam’s work over more than two decades has yielded the critical breakthroughs and advancements that have made the field of (RNAi) therapeutics possible. In 2018, our first commercial medicine, and the world’s first RNAi therapeutic was approved. Since then, five more Alnylam-developed medicines have been approved and we’re hard at work developing new therapies to treat both rare and prevalent diseases. We are a global and diverse company of 2,600+ people. We pride ourselves on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we’re consistently ranked as a top employer by The Boston Globe (2015-24), Science Magazine (2018-25), Fast Company (Best Workplaces for Innovators 2020-25) and LinkedIn (2024). We are based in Cambridge, Massachusetts (U.S.), with offices throughout North America, Europe, Asia, and South America. See our social media community guidelines: https://bit.ly/2FcRhJy. Please note: If you wish to report an adverse event or product complaint, please email [email protected] or you may call us using the following telephone numbers: for North America, 877.ALNYLAM (877.256.9526), for Europe, +31 20 369 7861 Fraudulent Recruitment Activity Be aware of the potential for scams and fraudulent recruitment activity from individuals claiming to represent Alnylam Pharmaceuticals. Alnylam never conducts its interview process via messaging apps, freelance sites, or social media platforms. Alnylam team members only communicate with potential candidates through an official Alnylam email address ending in "@alnylam.com."
解鎖市場時間軸與訊號動態
過去 90 日內有 6 個訊號。
此公司進入各市場的次序 — 由最舊至最新
Sr Manager, Medical Science Liaison - LOMBARDIA EST / TRIVENETO
Director, Medical Affairs
註冊以查看完整訊號動態
Alnylam Pharmaceuticals 的國際擴張與競爭對手的比較
長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
Alnylam Pharmaceuticals你 | 5 | 2 | 0% | 6 | 33 |
Scientist, Process Sciences
查看招聘Cambridge, MA · 上星期
Medical Science Liaison, Lead (Associate Director) - Italy
查看招聘Greater Rome Metropolitan Area · 上星期
Medical Science Liaison, Lead (Associate Director) - Italy
查看招聘Milan, Lombardy, Italy · 上星期
無進行中的廣告活動
註冊以追蹤此公司,並在發生變化時第一時間獲得提醒。
納斯達克宣布自2025年12月22日起,將有六家公司加入納斯達克100指數,包括Alnylam製藥和Ferrovial SE。
納斯達克100指數上漲1.58%,半導體股大幅反彈。美光科技領漲9.87%,KLAC、AMAT、ASML等晶片設備製造商也大幅上漲。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Alnylam Pharmaceuticals 業務、市場及增長訊號的快速解答。
